Basic Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. May 15, 2025; 16(5): 102196
Published online May 15, 2025. doi: 10.4239/wjd.v16.i5.102196
Shenfushu granules attenuate diabetic kidney disease by inhibiting PIK3R1/protein kinase B/heparanase-mediated endothelial-mesenchymal transition
Xi-Ding Yang, Si-Jia Ma, Da-Xiong Xiang, Yong-Yu Yang
Xi-Ding Yang, Si-Jia Ma, Da-Xiong Xiang, Yong-Yu Yang, Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China
Author contributions: Yang XD contributed to writing original draft, methodology, investigation; Ma SJ contributed to writing, review and editing; Xiang DX contributed to data curation, funding acquisition, conceptualization; Yang YY contributed to data curation, writing, review and editing, funding acquisition, conceptualization.
Supported by the Changsha Science and Technology Major Project, No. kh2205035; the Hunan Traditional Chinese Medicine Science and Technology Project, No. 2021061; and the Natural Science Foundation of Hunan Province, No. 2025JJ80080.
Institutional review board statement: This study does not involve any human experiments.
Institutional animal care and use committee statement: This animal study was reviewed and approved by The Second Xiangya Hospital of Central South University’s Animal Ethics and Welfare Committee (No. 2021558).
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yong-Yu Yang, MD, Associate Professor, Department of Pharmacy, The Second Xiangya Hospital of Central South University, No. 139 Renmin Middle Road, Furong District, Changsha 410011, Hunan Province, China. yongyuyang@csu.edu.cn
Received: October 14, 2024
Revised: February 9, 2025
Accepted: March 18, 2025
Published online: May 15, 2025
Processing time: 195 Days and 6.1 Hours
Core Tip

Core Tip: Shenfushu granules (SFSGs) can delay the progression of diabetic kidney disease (DKD) by reducing the levels of serum creatinine, urea nitrogen, and urinary microalbumin in DKD mice and reducing damage to glomeruli. SFSGs reduce glomerular endothelial-mesenchymal transition, which is characterized by filtration barrier damage. SFSGs affect the endothelial-mesenchymal transition mediated by the PIK3R1/protein kinase B/heparanase-1 signaling pathway. The main active ingredient of SFSGs strongly binds with PIK3R1.